A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y₁₂ inhibitor, compared with clopidogrel in healthy humans

Abstract

Compared with clopidogrel 75 mg, prasugrel 10 mg and 20 mg daily for 10 days resulted in more rapid, more consistent, and higher levels of platelet inhibition.